This week, PharmaCompass continued its analysis of the top 10 fastest-growing drugs of 2016 by sales to evaluate the drugs that registered large sales growth. Please note that these are not the top-selling drugs, but are the top 10 drugs that registered the maximum growth in global sales over 2015. Interestingly, things didn’t appear that[…]
Chemical entities SHINE in the top 10 fastest-growing drugs of 2016
Anti-Retroviral / Anti-HIV, Blood Product, Chemotherapeutic / Anti-Neoplastic, Drug Research & Development API, FDA Approved 2014, FDA Approved 2015 Tags: GileadPfizer May 26, 2017
FDA Approves Dorzolamide for Lowering Intraocular Pressure
Drug Research & Development API, FDA Approved 2014, OTC and Compounding Product Tags: glaucomahypertensionintraocular pressure May 04, 2015
In late 2014 the FDA approved Dorzolamide Hydrochloride, to be used in conjunction with Timolol Maleate for the treatment of increased intraocular pressure in patients with ocular hypertension or open-angle glaucoma. Known as the brand name eye drop Cosopt Opthamolic Solution, which is marketed by Lannett Company Inc., this solution has proven to be both[…]
Liraglutide FDA Approval Brings First Ever Injectable Weight Loss Drug
Anti-Diabetic, Anti-Obesity Product, FDA Approved 2014 Tags: LiraglutideUnited States Jan 26, 2015
The close of 2014 brought exciting news for Novo Nordisk’s innovative weight loss drug Saxenda. The Liraglutide FDA approval is the first of its kind as it’s the only available injectable treatment for obesity. The FDA overwhelmingly gave a nod to this easy to use form of Liraglutide as a safe and effectual option for[…]
Steady Growth Anticipated for Contrast Media Injectors like FDA Approved Iopamidol
Drug Research & Development API, FDA Approved 2014 Jan 08, 2015
An ongoing rise in imaging procedures, such as CT scans, PET scans, ultrasounds and MRIs has created a consistent demand for effectual contrast media injectors. Iopamidol has recently captured the attention of pharmaceutical research and development teams with an unprecedented FDA nod. At the close of November 2014 the FDA approved Iopamidol as a first[…]
FDA Approves Efficacious and Long-Acting MS Drug Alemtuzumab
Chemotherapeutic / Anti-Neoplastic, Drug Research & Development API, FDA Approved 2014, Monoclonal Antibodies / mAb Tags: AlemtuzumabLemtradaMS Nov 19, 2014
Alemtuzumab, also known as the brand name MS drug Lemtrada, has recently gained a long awaited FDA approval. Genzyme spent over a decade developing this long-acting agent designed to effectively treat patients with relapsing Multiple Sclerosis. The unique method of dispensing Alemtuzumab is a significant plus for patients who do not tolerate current medication regimens[…]
Xigduo FDA Approved for Once Daily Type 2 Diabetes Treatment
Anti-Diabetic, Blood Glucose Regulator, FDA Approved 2014, OTC and Compounding Product Tags: Australiatype 2 Diabetes Nov 03, 2014
British-Swedish drugmaker AstraZeneca has been approved by the FDA for its once-a-day Xigduo XR extended-release tablet to treat adults with type 2 diabetes mellitus in the United States. AstraZeneca’s once-daily tablet is indicated as an adjunct therapy to diet and exercise to improve glycaemic control. Xigduo XR is already approved in Australia, and Xigduo is[…]
Tavaborole Approved as Antifungal Toenail Treatment
Anti-Fungal, Drug Research & Development API, FDA Approved 2014 Oct 20, 2014
Anacor Pharmaceuticals, Inc. ANAC, announced on Jul 08, 2014 that the FDA has approved the New Drug Application for Tavaborole, which is marketed as KERYDIN™ topical solution, 5%. Tavaborole was designed to be convenient for patients to use and it’s the first oxaborole antifungal approved for the topical treatment of onychomycosis of the toenails. Onychomycosis[…]
Idelalisib EU Approval Granted For Treating CLL and FL Patients
Chemotherapeutic / Anti-Neoplastic, Drug Research & Development API, FDA Approved 2014 Tags: chronic lymphocytic leukemiaCLLIdelalisibRituximab Sep 24, 2014
Gilead Sciences has been granted marketing authorization by the European Commission for its Idelalisib 150mg tablets (to be marketed as Zydelig) to treat the two incurable blood cancers Chronic Lymphocytic Leukemia (CLL) and Follicular Lymphoma (FL). This formidable first-in-class oral inhibitor of phosphoinositide 3-kinase (PI3K) delta, plays a key role in the activation, proliferation and[…]
FDA Approves Contrave – A Naltrexone Hydrochloride and Bupropion Hydrochloride Drug Combo
Anti-Obesity Product, Drug Research & Development API, FDA Approved 2014, OTC and Compounding Product Tags: BMIhigh blood pressure Sep 12, 2014
On September 10, 2014, The U.S. Food and Drug Administration (US FDA) approved Contrave (naltrexone hydrochloride and bupropion hydrochloride extended-release tablets) for anti-obesity treatments in combination with a reduced-calorie diet and exercise. Contrave is distributed by Takeda Pharmaceuticals America Inc. of Deerfield, Illinois for Orexigen Therapeutics, Inc. of La Jolla, California. The FDA approved the[…]
FDA Approves Fluticasone Furoate for Once-Daily Asthma Therapy
Anti-Asthma / COPD, Drug Research & Development API, FDA Approved 2014, Respiratory Tract Agent Tags: asthma Aug 27, 2014
GlaxoSmithKline has announced that the FDA has approved fluticasone furoate inhalation powder, as a once-daily inhaled corticosteroid (ICS) medicine for maintenance treatment of asthma as preventative therapy in patients 12 and up. This therapy is only intended to prevent an asthma attack, not to treat it once it happens. For treating an asthma attack, one[…]
